Rachel L Sabado, PhD
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
Research Topics:AIDS/HIV, Antigen Presentation, Cancer, Dendritic Cells, Immunology, Lymphocytes, T Cells, Vaccine Development, Viruses and Virology
Several approaches have been taken to enhance immunity against tumors and infectious diseases in humans. These strategies target either the adaptive immune responses, i.e T cells and B cells, or enhance the activity of antigen presenting cells (APC) such as dendritic cells (DC). Dr. Sabado, as the Director of the Vaccine and Cell Therapy Laboratory (VCTL), is involved in developing new approaches to enhance the activity of DC to induce effective immune responses against tumors and infectious diseases in vivo. See the VCTL website for more information: http://labs.icahn.mssm.edu/sabadolab/
Sabado RL, Bhardwaj N. Dendritic cell immunotherapy. Annals of the New York Academy of Sciences 2013 May; 1284.
Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F, Bhardwaj N. Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. Journal of visualized experiments : JoVE 2013;(78).
Miller E, Spadaccia M, Sabado R, Chertova E, Bess J, Trubey CM, Holman RM, Salazar A, Lifson J, Bhardwaj N. Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Vaccine 2015 Jan; 33(2).
Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg JD, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer immunology research 2015 Mar; 3(3).